GLORY-1 phase 3 obesity trial
A 2025 NEJM phase 3 trial in 610 Chinese adults reported 11 to 14 percent body weight reduction on 4 to 6 mg against 0.3 percent on placebo over 48 weeks. Reported in the cited paper.
SourceBack to search
Weight LossMetabolic
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist from Innovent Biologics, licensed from Eli Lilly. It was approved in China in June 2025 for weight management and in September 2025 for type 2 diabetes. It is not approved in the United States or Europe.
- Lowest cost / mg
- $5.75/mg
- at Peptide Labs Inc
- Vendors listed
- 5
- In stock
- 6 of 6
- listings
- COA reports
- 5
Vendor listings
Compare Mazdutide prices.
Show prices as
6 listings · Mazdutide
In stock5mgseen 4d ago
In stock10mgseen 4d ago
In stock5mgseen 5d ago
In stock10mgseen 5d ago
In stock10mgseen 4d ago
- Peptide Labs IncLowest $/mg
In stock10 mg · 10 vialsseen 3d ago
Overview
What is Mazdutide?
Mazdutide is a dual GLP-1 and glucagon receptor agonist from Innovent Biologics, licensed from Eli Lilly. It was approved in China in June 2025 for weight management and in September 2025 for type 2 diabetes. It is not approved in the United States or Europe.
- Weight Management
- Glycemic Control
- Dual Mechanism
- Metabolic Health
What the research reports
Reported benefits of Mazdutide
Outcomes described across the published Mazdutide literature and ongoing study. Read each as research context rather than a promised personal result.
- 01
Dual GLP-1 and glucagon action
Pairs GLP-1 appetite suppression with glucagon driven energy expenditure, a mechanism distinct from GLP-1 only agonists. Reported in research settings.
- 02
Weight loss results in trials
GLORY-1 reported 11 to 14 percent weight reduction at 4 and 6 mg over 48 weeks against 0.3 percent on placebo in Chinese adults. Reported in research settings.
- 03
Higher dose weight outcomes
GLORY-2 tested 9 mg and reported up to 20.1 percent weight loss over a year in Chinese adults with obesity and no type 2 diabetes. Reported in research settings.
- 04
Glycaemic control outcomes
Phase 2 and 3 diabetes work reported HbA1c reductions of 1.41 to 1.67 percent alongside weight loss of up to 7.1 percent. Reported in research settings.
- 05
Comparator trial performance
A phase 3 trial reported superiority to dulaglutide on both HbA1c and body weight in 731 Chinese adults with type 2 diabetes. Reported in research settings.
Dosage and protocol
How Mazdutide is typically studied
Protocols escalate from 3 mg weekly for four weeks, to 4.5 mg, then 6 mg. Obesity trials also tested a 9 mg target dose weekly. Figures describe study protocols, not a personal regimen.
- Route
- Subcutaneous injection
- Example range
- 3-9 mg
- Frequency
- Once weekly
- Timing
- Once weekly on a consistent day, with or without meals. Escalation limits GI effects.
Clinical evidence
Clinical evidence for Mazdutide
The published Mazdutide record, labeled by strength so you can see what is settled and what is still emerging.
Dulaglutide comparison results
A 2025 Nature phase 3 trial in 731 Chinese adults with type 2 diabetes reported superiority to dulaglutide on both HbA1c and body weight over 28 weeks. Reported in the cited paper.
SourcePhase 2 diabetes safety trial
A 2024 Diabetes Care phase 2 trial in 250 Chinese patients reported HbA1c down 1.41 to 1.67 percent with body weight down by as much as 7.1 percent. Reported in the cited paper.
SourceInteractions
How Mazdutide pairs with other peptides
- Semaglutide
- Overlapping GLP-1 activity with no trial support for combining the two agents together. Confidence: emerging.
- Tirzepatide
- Both are incretin based agonists. Stacking adds gastrointestinal burden without established benefit.
- Insulin therapy
- The glucagon component affects hepatic glucose output, so glucose monitoring matters more here.
- Sulfonylureas
- Combined glucose lowering raises hypoglycaemia risk and warrants a prescribing review first.
Questions
Frequently asked questions.
What is Mazdutide?
Mazdutide is a peptide compound used in research settings. It is commonly studied for its role in weight loss, metabolic, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of Mazdutide?
Mazdutide is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does Mazdutide work?
Like other research peptides, Mazdutide is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is Mazdutide for research use only?
Yes, products like Mazdutide are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying Mazdutide?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
